Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Moodys
Healthtrust
Covington
UBS
Queensland Health
Cantor Fitzgerald
Dow
Farmers Insurance

Generated: August 18, 2018

DrugPatentWatch Database Preview

Merz Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for MERZ PHARMS, and what generic alternatives to MERZ PHARMS drugs are available?

MERZ PHARMS has two approved drugs.

There are two US patents protecting MERZ PHARMS drugs.

Summary for Merz Pharms
US Patents:2
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Merz Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merz Pharms CUVPOSA glycopyrrolate SOLUTION;ORAL 022571-001 Jul 28, 2010 RX Yes Yes 7,816,396 ➤ Sign Up ➤ Sign Up
Merz Pharms CUVPOSA glycopyrrolate SOLUTION;ORAL 022571-001 Jul 28, 2010 RX Yes Yes 7,638,552 ➤ Sign Up ➤ Sign Up
Merz Pharms ERYMAX erythromycin SOLUTION;TOPICAL 062508-002 Jul 11, 1985 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for MERZ PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Oral Solution 1 mg/5 mL ➤ Subscribe 2012-06-20

Non-Orange Book US Patents for Merz Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,091,236 Method for increasing the bioavailability of glycopyrrolate ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Boehringer Ingelheim
Harvard Business School
Citi
Medtronic
UBS
Chubb
Cipla
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.